Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Adeno-associated viruses (AAVs) are promising viral vectors for therapeutic gene delivery, and the approval of an AAV1 vector for the treatment of lipoprotein lipase deficiency has heralded a new and exciting era for this system. However, preclinical and clinical studies show that neutralization from pre-existing antibodies is detrimental for medical application and this hurdle must be overcome before full clinical realization can be achieved. Thus the binding sites for capsid antibodies must be identified and eliminated through capsid engineering. Towards this goal and to recapitulate patient polyclonal responses, a panel of eight new mouse monoclonal antibodies (MAbs) has been generated against AAV8 and AAV9 capsids, two vectors in development for therapeutic application. Native (capsid) dot blot assays confirmed the specificity of these antibodies for their parental serotypes, with the exception of one MAb, HL2372, selected to cross-react against both capsids. Furthermore, in vitro assays showed that these MAbs are capable of neutralizing virus infection. These MAbs will be utilized for structural mapping of antigenic footprints on their respective capsids to inform development of the next generation of rAAV vectors capable of evading antibody neutralization while retaining parental tropism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…deficiency (Pollack 2012), and numerous clinical trials are in progress for many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 2013; Wierzbicki et al. 2013).”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“AAV8 is known for its enhanced hepatic cell transduction (Sands 2011) and has been used in numerous preclinical and clinical trials to target the liver (Bell et al. 2011; Nathwani et al. 2007; Nathwani et al. 2006; Nathwani et al. 2011).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“…deficiency (Pollack 2012), and numerous clinical trials are in progress for many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 2013; Wierzbicki et al. 2013).”
BackgroundGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 2×
“AAV9 has been reported to cross the blood-brain barrier (Bevan et al. 2011; Federici et al. 2012; Gray et al. 2011; Schuster et al. 2014; Zhang et al. 2011), and has become the vector of choice for treating genetic disease involving the central nervous system (CNS) (Cearley et al.”
BackgroundAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 2×
“…lipoprotein lipase deficiency (Pollack 2012), and numerous clinical trials are in progress for many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 2013;…”
BackgroundSelf-citationZhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 2×
“AAV9 has been reported to cross the blood-brain barrier (Bevan et al. 2011; Federici et al. 2012; Gray et al. 2011; Schuster et al. 2014; Zhang et al. 2011), and has become the vector of choice for treating genetic disease involving the central nervous system (CNS) (Cearley et al.”
BackgroundWobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 1×
“(A) Position map of AAV serotypes and B1 antibody (Wobus et al. 2000) reactivity of AAV1-AAV9, the representative members of the AAV antigenic clades and clonal isolates (Gao et al. 2004).”
Method
Cited by
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Gorovits, B., Azadeh, M., Buchlis, G., Harrison, T., Havert, M., Jawa, V., Long, B., McNally, J., Milton, M., Nelson, R., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00628-3 · Cited by 53
Jose, A., Mietzsch, M., Smith, J. K., Kurian, J., Chipman, P., McKenna, R., Chiorini, J., & Agbandje-McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01394-18 · Cited by 44
Self-citationStructure comparison of the chimeric AAV2.7m8 vector with parental AAV2
Bennett, A., Keravala, A., Makal, V., Kurian, J., Belbellaa, B., Aeran, R., Tseng, Y.-S., Sousa, D., Spear, J., Gasmi, M., et al. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2019.107433 · Cited by 33
“Large loops interconnect the secondary structure elements with regions of high variability between different serotypes defined as VR-I to VR-IX based on two diverse serotypes, AAV2 and AAV4 (Govindasamy et al., 2006).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Tseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M.
- Venue
- Journal of Virological Methods
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 236
- Pages
- 105-110
- ISSN
- 0166-0934 (ISSN-L)
- OpenAlex
- W2464528200
- Cited by
- 28
- References
- 19
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. https://app.cochat.ai/papers/10.1016/j.jviromet.2016.07.009
- The paper
- Tseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M. (2016). Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. Journal of Virological Methods. https://doi.org/10.1016/j.jviromet.2016.07.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.